Tilianin shields the heart from doxorubicin by curbing mitophagy-driven ferroptosis
- Tilianin, a flavonoid from the Uyghur herb Dracocephalum moldavica, was tested against doxorubicin cardiotoxicity in H9c2 cardiomyocytes and mice.
- Transcriptomics plus mitochondrial modulators and ferrostatin-1 indicated that doxorubicin drives excessive mitophagy, mitochondrial iron release and lipid peroxidation, culminating in ferroptosis.
- Tilianin dampened this mitophagy, partly restored iron balance, and improved cardiac function and reduced myocardial injury, supporting a cardioprotective adjunct for chemotherapy.
💡 Points Based on the abstract
The mechanism is tidy, but doxorubicin protection is only worth pursuing if the antitumor effect survives. Iron chelation with dexrazoxane is the benchmark, and it has its own debate over this very issue. I'd want tumor-bearing mice with tilianin on board, a head-to-head against dexrazoxane, and plasma exposure data, since flavonoids often have poor oral bioavailability.